ERBB2 and gastric carcinoma: Approximately 15–20% of gastric carcinoma/gastric and gastroesophageal junction carcinoma (GC/GEJC) and 12–23% of breast cancers (BC) overexpress HER2 (Study Group HER2 Monitor, 2011).